Skip to content

Rapport Therapeutics

US · RAPP #2970 by market cap Listed 2024
23.16 -0.43 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Company notice
    CrossFirst Bankshares | 4: Statement of changes in beneficial ownership of securities-Officer Rapp W. Randall
    SEC · 2025/2/27
  • Rating change
    Goldman Sachs Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/10/22
  • Rating change
    A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $50 to $91
    Market Newswire · 2026/10/21
  • Rating change
    Analysts' Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)
    TipRanks · 2026/10/21
  • Rating change
    Guggenheim Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/10/22
  • Rating change
    Rapport Therapeutics, Inc. (RAPP) Gets a Buy From Goldman Sachs
    TipRanks · 2026/10/22
  • H.C. Wainwright Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Cuts Target Price to $63
    Market Newswire · 2026/11/6
  • Company notice
    CrossFirst Bankshares(Delisted) | 4: Statement of changes in beneficial ownership of securities-Officer Rapp W. Randall
    SEC · 2025/3/5
  • Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $47
    Market Newswire · 2026/11/6
  • Company notice
    The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.
    SEC · 2026/1/27
  • Rating change
    Wells Fargo Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)
    TipRanks · 2026/10/18
  • JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $82
    Market Newswire · 2026/11/12
  • Company notice
    The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.
    SEC · 2026/2/11
  • Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Cuts Target Price to $47
    Market Newswire · 2026/11/5
  • Rating change
    Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/10/22
  • UBS Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $64
    Market Newswire · 2026/11/6
  • Rating change
    JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $82
    Market Newswire · 2026/10/22
  • Rating change
    Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $51
    Market Newswire · 2026/10/20
  • Company notice
    The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.
    SEC · 2026/1/23
  • Rating change
    Wolfe Research Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/10/15
  • Rating change
    Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and The Estée Lauder Companies (EL)
    TipRanks · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $66 to $66
    Market Newswire · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $66 to $75
    Market Newswire · 2026/9/23
  • Rating change
    BTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)
    TipRanks · 2026/10/2
  • Rating change
    BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/10/2

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Rapport Therapeutics discussion 0 comments

Add a comment